Please assess the completion status of the following clinical trial:

Trial Title: Longitudinal Antimalarial Combinations in Uganda

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Phase I~* Age 1 to 10 years.~* Agreement to come to the study clinic for any febrile episode or other illness.~* Agreement to avoid medications administered outside the study.~* Willingness of parents or guardians to provide informed consent.~Phase II~* Child and Guardian/Parent belong to household currently enrolled in the study.~* Age 1 to 10 years.~* Agreement to come to the study clinic for any febrile episode or other illness.~* Agreement to avoid medications administered outside the study.~* Willingness of parents or guardians to provide informed consent.~Exclusion Criteria:~Phase I~* History (obtained from the parent/guardian) of any known serious chronic disease requiring frequent medical care (e.g. AIDS, sickle cell disease, malignancy).~* Intention to move from Kampala during the follow-up period.~* History (obtained from the parent/guardian) of serious side effects to study medications or sulfa drugs.~* Weight \< 10 kg~* Severe malnutrition defined as weight-for-height or height-for-age Z-score \<-3.~* Homozygous hemoglobin SS (sickle cell) result by hemoglobin electrophoresis.~* Life-threatening screening laboratory value in the absence of malaria:~* Absolute neutrophil count: \< 250/mm\^3~* Hemoglobin: \< 5.0 g/dL~* Platelet count: \< 25,000/mm\^3~* Creatinine: \< 2 years: \> 1.5 mg/dL, greater than or equal to 2 years: \> 2.0 mg/dL~* ALT: \> 15.0 x ULN~* Bilirubin: \> 7.5 x ULN Phase II~* History of any known serious chronic disease requiring frequent medical attention (e.g. AIDS, sickle cell disease, malignancy)~* Intention to move from Kampala during the follow-up period~* Any history of serious side effects to study medications~* Weight \< 10 kg~* Severe malnutrition~* Life-threatening screening laboratory test result

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).